Nanobiotix stock hinges on J&J’s JNJ-1900 Phase 3 success, with delayed catalysts and lender claims pressuring upside. Click here to read more on NBTX.
Nanobiotix (ENXTPA:NANO) is back in focus after releasing updated Phase 1 data for JNJ-1900, or NBTXR3, in anti-PD-1-resistant advanced primary cutaneous melanoma treated with radiotherapy plus checkpoint inhibitors. The fresh melanoma data has arrived at a time when Nanobiotix has already seen a sharp swing in sentiment, with a 49.71% 7-day share price return and a 48.53% year-to-date share price return, offset by a weaker 90-day share price return of 14.07% and a very large 3-year total...
New CFO appointment reshapes Nanobiotix leadership focus Nanobiotix (ENXTPA:NANO) has refreshed its top finance role, naming Arnd Christ as chief financial officer and executive board member after the departure of long-serving executive Bart Van Rhijn. Christ arrives with more than two decades in biotech finance across Europe and the United States, including prior CFO roles at several listed and private drug developers. His background may influence how Nanobiotix approaches funding,...
PARIS and CAMBRIDGE, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced the appointment of Arnd Christ as chief financial officer and member of the Company’s executive board, effective October 1, 2026. Mr. Christ brings more than two decades of financial leadership in
Detailed price information for Damora Therapeutics Inc (DMRA-Q) from The Globe and Mail including charting and trades.
Promising early results reported from full cohort analysis of the completed dose-escalation and expansion phases of a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with inoperable, locoregionally recurrent non-small cell lung cancer (“NSCLC”) amenable to re-irradiationStrengthened financial position through an oversubscribed ~€86 million global follow-on offering completed in May 2026, extending cash runway into 2029Acceptable safety profile and promising initial efficacy responses obs
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of Shares OutstandingTotal number of voting rightsTotal voting rights, theoretical1Total voting rights, exercisab
Nanobiotix S.A. (NASDAQ:NBTX) reported September 14 results from all 24 patients in the dose-escalation and expansion portions of a Phase 1 study of JNJ-1900, also called NBTXR3, combined with repeat radiation. The study enrolled patients with inoperable, locoregionally recurrent non-small cell lung cancer. Nanobiotix S.A. (NASDAQ:NBTX) reported 79% one-year locoregional control at a median follow-up […]
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (
All 24 patients completed treatment with no dose-limiting toxicities, no Grade 3 or higher adverse events related to JNJ-1900 (NBTXR3 or to the injection procedure, and intratumoral injection was deemed feasibleOne-year locoregional control rate was 79%, one-year local progression-free survival (LPFS) was 61%, and one-year overall survival (OS) was 70% in evaluable subjects— achieved at a lower re-irradiation dose than patients’ prior course of radiotherapyInvestigators concluded that JNJ-1900 (
PARIS and CAMBRIDGE, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-stage clinical biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer and other major diseases, today announced that Company management will participate in a fireside chat at the following investment conference: H.C. Wainwright 28th Annual Global Investment ConferenceDate: Tuesday, September 15, 2026Time: 1
PARIS and CAMBRIDGE, Mass., June 02, 2026 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the “Company”), a late-clinical stage...
In accordance with articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Market: Euronext Paris / NasdaqEuronext Compartment: B ISIN code: FR0011341205Nasdaq: NBTXBloomberg: NANO:FPReuters: NANO.PAWebsite: www.nanobiotix.com DateNumber of SharesOutstandingTotal number of voting rightsTotal voting rights,theoretical1Total voting rights,exercisable2J
This is the newest page. Registered accounts read further back.